Last quarter (Q2 2022), Wuxi Biologics (Cayman)'s total revenue was ¥―, a decrease of ― from the same quarter last year. In Q2, Wuxi Biologics (Cayman)'s net income was ¥―. See Wuxi Biologics (Cayman)’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	¥ 10.29B	¥ 5.61B	¥ 3.98B	¥ 2.53B	¥ 1.62B
Cost of Revenue	-	¥ 5.46B	¥ 3.08B	¥ 2.32B	¥ 1.52B	¥ 958.27M
Gross Profit	-	¥ 4.83B	¥ 2.53B	¥ 1.66B	¥ 1.02B	¥ 660.56M
Operating Expense	-	¥ 1.36B	¥ 771.43M	¥ 601.77M	¥ 323.62M	¥ 210.17M
Operating Income	-	¥ 3.46B	¥ 1.76B	¥ 1.06B	¥ 694.14M	¥ 450.38M
Net Non Operating Interest Income Expense	-	¥ 18.84M	¥ 38.13M	¥ 44.25M	¥ 78.39M	¥ -26.95M
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	¥ 3.99B	¥ 1.97B	¥ 1.13B	¥ 737.72M	¥ 303.69M
Tax Provision	-	¥ 484.54M	¥ 273.07M	¥ 116.30M	¥ 107.26M	¥ 51.06M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	¥ 3.39B	¥ 1.69B	¥ 1.01B	¥ 630.59M	¥ 252.63M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	¥ 6.83B	¥ 3.85B	¥ 2.93B	¥ 1.84B	¥ 1.17B
Net Income From Continuing And Discontinued Operation	-	¥ 3.39B	¥ 1.69B	¥ 1.01B	¥ 630.59M	¥ 252.63M
Normalized Income	-	¥ 3.24B	¥ 1.47B	¥ 981.18M	¥ 749.19M	¥ 271.77M
Interest Expense	-	¥ 39.19M	¥ 42.73M	¥ 19.61M	¥ 0.00	¥ 35.69M
EBIT	-	¥ 4.03B	¥ 2.01B	¥ 1.15B	¥ 737.72M	¥ 339.38M
EBITDA	-	¥ 4.51B	¥ 2.31B	¥ 1.37B	¥ 881.49M	¥ 426.86M

Currency in CNY

Wuxi Biologics (Cayman) Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing